NCT07028853: An ongoing trial by Pfizer
This trial is ongoing. It must report results 3 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07028853 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 28, 2025 |
| Completion date | Sept. 12, 2028 |
| Required reporting date | Sept. 12, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |